Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Sichuan Kelun-Biotech
6990Current price
161.5 HKD
-2.8 HKD (-1.70%)
Last closed
165.6 HKD
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
Hong Kong Stock Exchange
Capitalization
37 530 638 958 HKD
Yield for 12 month
+79.64 %
1Y
3Y
5Y
10Y
15Y
6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People's Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336. The company has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd. Address: No. 666 Xinhua Avenue, Chengdu, China
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1 677.46 HKDP/E ratio
–Dividend Yield
–Current Year
+804 968 483 HKD
Last Year
+32 363 631 HKD
Current Quarter
+1 047 573 561 HKD
Last Quarter
+459 536 132 HKD
Current Year
+527 783 927 HKD
Last Year
+11 812 192 HKD
Current Quarter
+676 530 264 HKD
Last Quarter
+301 603 972 HKD
Key Figures 6990
1 year
3 years
5 years
10 years
EBITDA
-142 572 389 HKD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-3.59 %
PEG Ratio
–
Return On Equity TTM
-17.35 %
Wall Street Target Price
1 677.46 HKD
Revenue TTM
1 879 475 741 HKD
Book Value
14.42 HKD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
32.2 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
–
Diluted Eps TTM
–
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
-12.4 %
Dividend Analytics 6990
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 6990
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 6990
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
17.6566
Price Sales TTM
19.9687
Enterprise Value EBITDA
–
Price Book MRQ
11.2183
Financials 6990
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 6990
For 52 weeks
63.73 HKD
224.09 HKD
50 Day MA
181.86 HKD
Shares Short Prior Month
–
200 Day MA
153.66 HKD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart